Fang, Douglas D.
Tao, Ran
Wang, Guangfeng
Li, Yuanbao
Zhang, Kaixiang
Xu, Chunhua
Zhai, Guoqin
Wang, Qixin
Wang, Jingwen
Tang, Chunyang
Min, Ping
Xiong, Dengkun
Chen, Jianyong
Wang, Shaomeng
Yang, Dajun
Zhai, Yifan
Funding for this research was provided by:
Ascentage Pharma Group Corp. Ltd
Article History
Received: 10 February 2022
Accepted: 31 May 2022
First Online: 11 July 2022
Declarations
:
: Protocols involving care and use of animals and the study were approved by Institutional Animal Care and Use Committees. All methods were carried out in accordance with relevant guidelines and regulations, and all methods are reported in accordance with Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines for the reporting of animal experiments (Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412).
: D. D. Fang, R. Tao, G. Wang, Y. Li, K. Zhang, C. Xu, G. Zhai, Q. Wang, J. Wang, C. Tang, P. Min, D. Xiong, J. Chen, D. Yang, and Y Zhai are full-time employees of Ascentage Pharma and equity shareholders of Ascentage Pharma Group International, the ultimate parent of Ascentage Pharma. S. Wang is a cofounder of Ascentage Pharma Group International, owns stock in the company, and receives grants and personal fees. He is a member of its board of directors, is its Chief Scientific Advisor, and is also a paid consultant. S. Wang and J. Chen hold an issued and licensed patent (US10709705B2) filed by the University of Michigan on APG-2449 and its analogs and receive royalties from the University of Michigan on this patent. The University of Michigan owns equity in, and has received research contracts from, affiliates of Ascentage Pharma for which S. Wang is the principal investigator. All other authors declare that they have no other competing interests.